Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) EBITDA (2021 - 2025)

Historic EBITDA for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to -$50.5 million.

  • Prime Medicine's EBITDA rose 359.94% to -$50.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.3 million, marking a year-over-year increase of 992.88%. This contributed to the annual value of -$195.9 million for FY2024, which is 95.97% up from last year.
  • Prime Medicine's EBITDA amounted to -$50.5 million in Q3 2025, which was up 359.94% from -$52.6 million recorded in Q2 2025.
  • Prime Medicine's 5-year EBITDA high stood at -$16.4 million for Q3 2021, and its period low was -$65.5 million during Q4 2023.
  • In the last 5 years, Prime Medicine's EBITDA had a median value of -$45.8 million in 2024 and averaged -$44.1 million.
  • The largest annual percentage gain for Prime Medicine's EBITDA in the last 5 years was 3768.69% (2022), contrasted with its biggest fall of 8096.05% (2022).
  • Quarter analysis of 5 years shows Prime Medicine's EBITDA stood at -$62.9 million in 2021, then soared by 37.69% to -$39.2 million in 2022, then tumbled by 67.06% to -$65.5 million in 2023, then soared by 35.43% to -$42.3 million in 2024, then dropped by 19.49% to -$50.5 million in 2025.
  • Its last three reported values are -$50.5 million in Q3 2025, -$52.6 million for Q2 2025, and -$51.9 million during Q1 2025.